Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.

The Annals of pharmacotherapy - 1 Mar 2013

Russo Paul A J, Wiese Michael D, Smith Malcolm D, Ahern Michael J, Barbara Jeffrey A, Shanahan E Michael

Abstract excerpt

OBJECTIVE: To study the pharmacokinetics and pharmacogenetics of leflunomide and document its efficacy and safety in the treatment of inflammatory arthritis in a patient with end-stage renal disease (ESRD) who was on peritoneal dialysis. CASE SUMMARY: Therapy for a 78-year-old man with ESRD who required peritoneal dialysis was started with leflunomide 10 mg/day for psoriatic arthritis. The dosage was increased to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Psoriatic

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Cytochrome P-450 CYP2C19

Share to Isoxazoles

Share to Kidney Failure, Chronic

Share to Peritoneal Dialysis

Source

Identifiers

PMID: 23447478
DOI: 10.1345/aph.1R542

Genes

ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.PMID 23447478Read ↗

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.Semantic proximity Read ↗

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.Semantic proximity Read ↗

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.Semantic proximity Read ↗

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Semantic proximity Read ↗

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsSemantic proximity Read ↗

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.Semantic proximity Read ↗

Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.Semantic proximity Read ↗

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.Semantic proximity Read ↗

The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisSemantic proximity Read ↗

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.Semantic proximity Read ↗

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.